CONTRAD SWISS
Carmen Gerardi MA, MSc, MBA is an accomplished professional with extensive experience in medical and marketing leadership. Currently serving as the Director of Medical and Marketing at CONTRAD SWISS, Carmen integrates medical science with strategic marketing to promote innovative regenerative medicine. Previous roles include Marketing Director at Fidia Pharma USA Inc, where a successful digital marketing strategy was implemented, and Vice President at GUNA, Inc., where Carmen led operational strategy and customer retention initiatives. Additionally, Carmen has served on the board of the Institute of Clinical Ecology, contributing to research on signaling molecules, and has held various marketing and operational positions in renowned companies such as Bayer Pharmaceuticals and Italfarmaco. With a strong educational background that includes an MBA and a Digital Marketing Certificate from Cornell University, Carmen demonstrates a robust commitment to driving growth and enhancing patient outcomes in the healthcare sector.
This person is not in any teams
CONTRAD SWISS
CONTRAD SWISS is a dynamic Swiss-based pharmaceutical corporation revolutionizing the regenerative medicine landscape. Headquartered in Lugano, Contrad Swiss is the owner of proprietary SIGMOLECS® Technology which takes the current use of peptides as active ingredients a giant step forward. The company portfolio comprises medical devices and aesthetic products, positioned in the premium segment, delivering unparalleled value. SIGMOLECS® is a unique technology guiding cell behaviour for a wide range of treatments. It talks to cells in their own language, enabling more effective therapies. It is designed to work with various treatment methods, following the body's natural systems and also enhancing the penetration of other important molecules. This breakthrough technology, utilizing customized peptide sequences, is the driving force behind our specialized non-invasive product lines in Orthopaedics (500Line), Aesthetic Medicine (ACTV8 PRO), and in our targeted alleviating lotion (Egyfil), all supported by recently published peer-reviewed studies. The 500Line, powered by SIGMOLECS®, addresses unmet clinical needs in osteoarthritis and connective tissue pathology through non-invasive, rapid-acting formulations. Egyfil offers targeted relief for muscle & joint stiffness and discomfort. ACTV8 PRO is designed for regenerative aesthetic physicians. CONTRAD SWISS is signaling the future of regenerative medicine.